News Quantified

ALNY – alnylam pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at JPMorgan Chase & Co. from $272.00 to $280.00. They now have a "neutral" rating on the stock.

WearOptimo Introduces World-Class Advisory Board to Further Advance Microwearable Sensor Technology for Precision Health Monitoring [Yahoo! Finance]

Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum

Dr. Phillip A. Sharp Retirement From Alnylam Pharmaceuticals (NasdaqGS:ALNY) Board Announced [Yahoo! Finance]

Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary [Yahoo! Finance]

-1.5%

BEAT

-1.5%

BEAT

-2.3%

BEAT

-1.9%

BEAT

Royal Bank of Canada

Royal Bank of Canada

Form 8-K ALNYLAM PHARMACEUTICALS, For: Mar 03

Form 4 ALNYLAM PHARMACEUTICALS, For: Mar 03 Filed by: Fitzgerald Kevin Joseph

Form 4 ALNYLAM PHARMACEUTICALS, For: Mar 03 Filed by: Tanguler Tolga

Form 4 ALNYLAM PHARMACEUTICALS, For: Mar 03 Filed by: Hesslein Robert W.

Form 4 ALNYLAM PHARMACEUTICALS, For: Mar 03 Filed by: Poulton Jeffrey V.

Top News Gainers

8/6 Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30 11.4%

11/19 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $128.00 price target on the stock. 10.5%

3/12 Why Alnylam Pharmaceuticals, Intuitive Surgical, and ResMed Stocks Sank Today [The Motley Fool] 9.1%

8/6 Form 8-K ALNYLAM PHARMACEUTICALS, For: Aug 06 6.3%

4/6 Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs 6.0%

11/18 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $120.00 price target on the stock. 5.6%

11/22 Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 20 Filed by: Greenstreet Yvonne 5.2%

10/31 Alnylam Pharmaceuticals, Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] 4.9%

11/26 Alnylam to Webcast Presentations at Upcoming December Investor Conferences 4.9%

2/9 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $154.00 price target on the stock. 4.8%

Top News Decliners

12/17 Alnylam gene-silencing therapy to treat kidney disorder succeeds in late-stage study [Reuters (UK)] -11.7%

3/10 Alnylam Pharmaceuticals (ALNY) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -6.9%

2/21 Form 4 ALNYLAM PHARMACEUTICALS, For: Feb 20 Filed by: MARAGANORE JOHN -6.7%

11/22 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Morgan Stanley from $124.00 to $141.00. They now have an "overweight" rating on the stock. -4.7%

4/13 Alnylam's stock surges after Blackstone confirms $2 billion investment [MarketWatch] -4.4%

9/26 Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference -4.3%

3/16 Alnylam shows wild action on a wild day [Seeking Alpha] -4.2%

5/3 Form SC 13G/A ALNYLAM PHARMACEUTICALS, Filed by: Sanofi -4.2%

9/6 Alnylam to Host Sixth Annual “RNAi Roundtable” Webcast Series -4.0%

1/10 Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1) -3.9%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day